UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/955,373	10/21/1997	SOREN MOURITSEN	BNIT0003-US	7254
98994 BN Immuno Th	7590 09/16/201 nerapeutics, Inc.	1	EXAMINER	
2425 Garcia Av	renue		SCHWADRON, RONALD B	
Mountain View, CA 94043-1106			ART UNIT	PAPER NUMBER
			1644	
			NOTIFICATION DATE	DELIVERY MODE
			09/16/2011	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

david.hoffman@bn-it.com

Notice of Non-Compliant Amendment (37 CFR 1.121)

Application No.	Applicant(s)
08/955,373	MOURITSEN ET AL.
Examiner	Art Unit
Ron Schwadron, Ph.D.	1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

The amendment document filed on $\underline{17\ June\ 2011}$ is consider requirements of 37 CFR 1.121 or 1.4. In order for the amend item(s) is required.					
THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE AME 1. Amendments to the specification: A. Amended paragraph(s) do not include mark B. New paragraph(s) should not be underlined C. Other	kings.				
2. Abstract:A. Not presented on a separate sheet. 37 CFFB. Other	R 1.72.				
"Annotated Sheet" as required by 37 CFR B. The practice of submitting proposed drawing	the top margin as "Replacement Sheet," "New Sheet," or 1.121(d). In a correction has been eliminated. Replacement drawings in compliance with 37 CFR 1.84 are required.				
C. Each claim has not been provided with the of each claim cannot be identified. Note: t number by using one of the following statu (Previously presented), (New), (Not entere	present. ext of all pending claims (including withdrawn claims) proper status identifier, and as such, the individual status the status of every claim must be indicated after its claim s identifiers: (Original), (Currently amended), (Canceled), d), (Withdrawn) and (Withdrawn-currently amended). not been presented in ascending numerical order.				
5. Other (e.g., the amendment is unsigned or not signed in accordance with 37 CFR 1.4):					
For further explanation of the amendment format required by	37 CFR 1.121, see MPEP § 714.				
TIME PERIODS FOR FILING A REPLY TO THIS NOTICE:					
Applicant is given no new time period if the non-compliant amendment is an after-final amendment or an amendment filed after allowance. If applicant wishes to resubmit the non-compliant after-final amendment with corrections, the entire corrected amendment must be resubmitted.					
Applicant is given one month , or thirty (30) days, whichever is longer, from the mail date of this notice to supply the correction, if the non-compliant amendment is one of the following: a preliminary amendment, a non-final amendment (including a submission for a request for continued examination (RCE) under 37 CFR 1.114), a supplemental amendment filed within a suspension period under 37 CFR 1.103(a) or (c), and an amendment filed in response to a <i>Quayle</i> action. If any of above boxes 1. to 4. are checked, the correction required is only the corrected section of the non-compliant amendment in compliance with 37 CFR 1.121.					
 Extensions of time are available under 37 CFR 1.136(a) only if the non-compliant amendment is a non-final amendment or an amendment filed in response to a <i>Quayle</i> action. Failure to timely respond to this notice will result in: Abandonment of the application if the non-compliant amendment is a non-final amendment or an amendment filed in response to a <i>Quayle</i> action; or Non-entry of the amendment if the non-compliant amendment is a preliminary amendment or supplemental amendment. 					
					Ron Schwadron, Ph.D. Primary Examiner, Art Unit 1644

Continuation of 3(c) Other: New drawings in response to the Office action of 7/14/99, paragraph 6 have never been filed. Figure 1 is unreadable in its current form.

Continuation of 4(e) Other: In claim 88, line 5, the comma after "epitopes" is underlined wherein the comma had already been previously added..